Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (382)	9/11/2003 4:23:48 PM
From: WhatsUpWithThat	Respond to of 3722

Did't get that close over 9 on INGN. Heavy vol day, but not a great showing IMO on such a positive day overall. Guess I'll sit back a bit and see what's going to happen with it. Thks WUWT

To: Jibacoa who wrote (382)	9/11/2003 4:26:28 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

As mentioned here earlier,Rodman & Renshaw started coverage of INGN this morning with a Mkt Outperform and a target $20 They stated that the stock's valuation does not reflect the mkt potential of its key driver, Advexin gene therapy, which they estimate could be a $1 bln worldwide mkt opportunity; also,they say that INGN 241 is an early but exciting pipeline prospect, <g> and they think that the stock's low valuation reflects the suspicion surrounding gene therapies in general and is unwarranted. IMHO, INGN 241 has an even greater potential than ADVEXIN, since pre-clinical trials have determined that INGN 241 suppresses growth of many cancer cells, including those of the breast, lung, colon, prostate and central nervous system, while not affecting growth of normal cells. While ADVEXIN depends on p53 been present, INGN 241 kills cancer cells, even if other tumor suppressor genes, including p53 or p16, are not functioning properly,and it appears that mda-7 functions via a novel mechanism of tumor suppression. In pre-clinical trials it seems that besides its known activity as a tumor suppressor gene, INGN 241 may also stimulate the body's immune system to protect it against cancer, thereby offering the potential of providing an added advantage in treating various cancers because it may attack cancer using two different mechanisms. INGN 241 may also work effectively as a radiation sensitizer to make several types of human cancer cells more susceptible to the anti-cancer effect of radiation therapy as indicated in its pre-clinical work. Introgen has also published results of a pre-clinical trial indicating that INGN 241 may suppress the growth in-vivo of non-small-cell lung cancer through apoptosis, in combination with anti-angiogenesis. Caveat: I am long,enthusiastic,hopeful,optimistic and enjoying a 400% run on INGN.<g> (I am already making plans for a celebration party if the stock gets to $20 while I am still alive.<g>) siliconinvestor.com Bernard